Jennifer Lachey - Keros Therapeutics Chief Officer
| KROS Stock | USD 53.84 0.30 0.55% |
Insider
Jennifer Lachey is Chief Officer of Keros Therapeutics
| Age | 51 |
| Address | 1050 Waltham Street, Lexington, MA, United States, 02421 |
| Phone | 617 314 6297 |
| Web | https://www.kerostx.com |
Jennifer Lachey Latest Insider Activity
Tracking and analyzing the buying and selling activities of Jennifer Lachey against Keros Therapeutics stock is an integral part of due diligence when investing in Keros Therapeutics. Jennifer Lachey insider activity provides valuable insight into whether Keros Therapeutics is net buyers or sellers over its current business cycle. Note, Keros Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Keros Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Jennifer Lachey over a month ago Disposition of 875 shares by Jennifer Lachey of Keros Therapeutics at 54.54 subject to Rule 16b-3 | ||
Jennifer Lachey over six months ago Disposition of 559 shares by Jennifer Lachey of Keros TherapeuticsInc at 64.15 subject to Rule 16b-3 |
Keros Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.2817) % which means that it has lost $0.2817 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4382) %, meaning that it created substantial loss on money invested by shareholders. Keros Therapeutics' management efficiency ratios could be used to measure how well Keros Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.43 in 2024. Return On Capital Employed is likely to drop to -0.52 in 2024. At this time, Keros Therapeutics' Non Current Assets Total are comparatively stable compared to the past year. Non Currrent Assets Other is likely to gain to about 2.2 M in 2024, whereas Net Tangible Assets are likely to drop slightly above 166.3 M in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Pablo MD | ZyVersa Therapeutics | N/A | |
| Anna Moore | Transcode Therapeutics | 62 | |
| John Cini | Sonnet Biotherapeutics Holdings | 71 | |
| Denise Carter | Quoin Pharmaceuticals Ltd | 55 | |
| Susan Dexter | Sonnet Biotherapeutics Holdings | 69 | |
| Jay Cross | Sonnet Biotherapeutics Holdings | 53 | |
| Robert Dudley | Transcode Therapeutics | 73 | |
| Michael Myers | Quoin Pharmaceuticals Ltd | 62 | |
| Karen Cashmere | ZyVersa Therapeutics | 72 | |
| LaBella MS | ZyVersa Therapeutics | 66 | |
| Qiyong Liu | Transcode Therapeutics | 60 | |
| MD FACP | Sonnet Biotherapeutics Holdings | 66 | |
| Dr MedSc | Phio Pharmaceuticals Corp | 68 | |
| Manuel Dafonseca | Sonnet Biotherapeutics Holdings | N/A | |
| Gordon JD | Quoin Pharmaceuticals Ltd | 60 | |
Management Performance
| Return On Equity | -0.44 | ||||
| Return On Asset | -0.28 |
Keros Therapeutics Leadership Team
Elected by the shareholders, the Keros Therapeutics' board of directors comprises two types of representatives: Keros Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Keros. The board's role is to monitor Keros Therapeutics' management team and ensure that shareholders' interests are well served. Keros Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Keros Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Robin Wagner, Senior Resources | ||
| Simon MBBS, Chief Officer | ||
| Keith MBA, Chief Officer | ||
| Christopher MSc, Chief Officer | ||
| John MBA, Senior Management | ||
| Jennifer Lachey, Chief Officer | ||
| Jasbir Seehra, CEO and President | ||
| Esther JD, General VP | ||
| Yung MD, Chief Officer |
Keros Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Keros Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.44 | ||||
| Return On Asset | -0.28 | ||||
| Operating Margin | (151.18) % | ||||
| Current Valuation | 1.68 B | ||||
| Shares Outstanding | 40.51 M | ||||
| Shares Owned By Insiders | 5.40 % | ||||
| Shares Owned By Institutions | 94.60 % | ||||
| Number Of Shares Shorted | 2.41 M | ||||
| Price To Book | 4.12 X | ||||
| Price To Sales | 3,369 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Keros Stock Analysis
When running Keros Therapeutics' price analysis, check to measure Keros Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Keros Therapeutics is operating at the current time. Most of Keros Therapeutics' value examination focuses on studying past and present price action to predict the probability of Keros Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Keros Therapeutics' price. Additionally, you may evaluate how the addition of Keros Therapeutics to your portfolios can decrease your overall portfolio volatility.